As more research on the therapeutic benefits of psychedelics is conducted, concerns about whether microdosing works continue to grow, as many believe that the supposed benefits may be solely because of the placebo effect. It doesn’t help that data from placebo-controlled trials is inconclusive, which only means that the best way to find out whether microdosing is actually effective is to carry out properly controlled microdosing clinical trials.
The following are a few of the ongoing microdosing clinical trials.
Filament Health’s psilocybin clinical trial
Earlier in the year, Filament Health announced that it was launching a phase II psilocybin microdosing clinical trial in collaboration with the University of Toronto. The trial’s objective is to look into the use of psilocybin microdoses as treatment for persistent depressive disorder. The trial will involve 50 patients with depression, half of whom will receive a placebo while the other half will receive 2mg of psilocybin once a week for four weeks.
If the trial finds that psilocybin microdosing is effective in treating depression, this will be good news for the more than 10% of individuals in America who are currently on antidepressants. Selective serotonin reuptake inhibitors, which are usually prescribed as antidepressants, aren’t effective in most individuals with depression and often cause side effects.
MindBio Therapeutics’ LSD microdosing trial
MindBio Therapeutics announced in March that by the end of 2022, it would begin its phase II trial on the use of LSD microdosing in alleviating depression and anxiety in patients in the advanced stages of cancer.
Individuals with cancer often suffer from acute depression and anxiety after receiving life-changing diagnoses, which could impact their recovery. Each study participant will receive a small dose of LSD once every three days.
In addition, the company is finishing the last touches on its phase I LSD microdosing trial, which focused on evaluating the safety of microdosing.
MindMed’s LSD microdosing trial
Last December, MindMed announced that it had begun recruiting participants for its phase IIa trial, which will evaluate the effectiveness of LSD microdoses in treating adults with ADHD. This will be the first-ever trial to try to treat ADHD using a psychedelic.
The trial will recruit 52 adults with ADHD, who will each receive 20mg of LSD or a placebo two times a week over a six-week period.
Many argue that LSD microdoses can improve mood, attentiveness and focus. If this is true, it will greatly benefit individuals with ADHD.
These trials are only a few of the ongoing or planned studies looking into the therapeutic effects of psychedelics. As companies such as Silo Pharma Inc. (OTCQB: SILO) press ahead with their drug development efforts, we will see more trials demonstrating the benefits or potential drawbacks of these novel pharmaceutical compounds.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.